Manzoli L, Billi A M, Gilmour R S, Martelli A M, Matteucci A, Rubbini S, Weber G, Cocco L
Institute of Human Morphology, University of Chieti, Italy.
Cancer Res. 1995 Jul 15;55(14):2978-80.
Previous investigations have demonstrated the presence of conventional lipid kinases and phospholipase C (PLC) activities in nuclei of Friend erythroleukemia cells. Moreover, when Friend erythroleukemia cells are treated for 96 h with the antitumor drug tiazofurin, the induction of erythroid differentiation is accompanied by changes in amounts of both phosphatidylinositol and phosphatidylinositol 4,5-bisphosphate due to the inhibition of an uncharacterized nuclear PLC activity. Here, we show that the nuclear PLC beta 1 isoform is down-regulated by tiazofurin (5 microM) treatment of Friend erythroleukemia cells as shown by both Western blot and Northern blot analyses for PLC beta 1 message. This indicates that PLC beta 1 down-regulation is tightly linked with erythroid differentiation of Friend erythroleukemia cells and that the autonomous nuclear signaling via inositol lipid cycle can be controlled by the antitumor drug tiazofurin.
先前的研究已证明,Friend红白血病细胞核中存在传统的脂质激酶和磷脂酶C(PLC)活性。此外,当用抗肿瘤药物替扎呋林处理Friend红白血病细胞96小时时,红系分化的诱导伴随着磷脂酰肌醇和磷脂酰肌醇4,5-二磷酸含量的变化,这是由于一种未明确的核PLC活性受到抑制所致。在此,我们表明,通过蛋白质免疫印迹法和针对PLCβ1信使的Northern印迹分析显示,用替扎呋林(5 microM)处理Friend红白血病细胞会使核PLCβ1亚型下调。这表明PLCβ1的下调与Friend红白血病细胞的红系分化紧密相关,并且通过肌醇脂质循环的自主核信号传导可由抗肿瘤药物替扎呋林控制。